tirzepatide options Zepbound Now Available Through LillyDirect: A New Option for Access at a Predictable Price What is the latest update

They stop treatment and, predictably, the weight comes back

Seek immediate medical care if you experience: severe, persistent abdominal pain (particularly if radiating to the back), which could indicate pancreatitis

During a 17-week off-treatment follow-up period, people who had stopped using tirzepatide began to regain weight, Lilly said in a news release, and there was some increase in the progression to type 2 diabetes. The most frequently reported adverse events were typically gastrointestinal-related and generally mild to moderate in severity, Lilly said

But generic will be available after the patent expires which will reduce the cost for patients